ライフサイエンスコーパス: antineutrophil cytoplasmic antibody

1 cerevisiae antibody (ASCA), and perinuclear antineutrophil cytoplasmic antibodies).

2 had a positive test for the myeloperoxidase antineutrophil cytoplasmic antibody.

3 out systemic disease occurs in patients with antineutrophil cytoplasmic antibodies.

4 All but 1 patient had antineutrophil cytoplasmic antibodies (ANCA) against pro

5 Antineutrophil cytoplasmic antibodies (ANCA) are positiv

6 Antineutrophil cytoplasmic antibodies (ANCA) are present

7 ost recent published literature in childhood antineutrophil cytoplasmic antibodies (ANCA) associated

8 Antineutrophil cytoplasmic antibodies (ANCA) binding to

9 Antineutrophil cytoplasmic antibodies (ANCA) directed ag

10 ith Wegener's granulomatosis associated with antineutrophil cytoplasmic antibodies (ANCA) directed ag

11 Antineutrophil cytoplasmic antibodies (ANCA) have been c

12 Two important types of antineutrophil cytoplasmic antibodies (ANCA) have been i

13 n Europe have established the association of antineutrophil cytoplasmic antibodies (ANCA) with vascul

14 s to detect antinuclear antibodies (ANA) and antineutrophil cytoplasmic antibodies (ANCA), along with

15 Two types of antineutrophil cytoplasmic antibodies (ANCA), antiprotei

16 The pathogenicity of antineutrophil cytoplasmic antibodies (ANCA), however, r

17 rom activation of circulating neutrophils by antineutrophil cytoplasmic antibodies (ANCA), resulting

18 Granulomatosis with polyangiitis (GPA) is an antineutrophil cytoplasmic antibodies (ANCA)-associated

19 s Wegener's granulomatosis, have circulating antineutrophil cytoplasmic antibodies (ANCA).

20 Patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) experience re

21 The increased availability of testing for antineutrophil cytoplasmic antibody (ANCA) has widened t

22 The utility of antineutrophil cytoplasmic antibody (ANCA) levels to gui

23 s to characterize these subgroups further by antineutrophil cytoplasmic antibody (ANCA) pattern and T

24 erulosclerosis (FSGS), infection-related GN, antineutrophil cytoplasmic antibody (ANCA) vasculitis, l

25 hese diseases, collapsing glomerulopathy and antineutrophil cytoplasmic antibody (ANCA) vasculitis-in

26 lness self-management for adults living with antineutrophil cytoplasmic antibody (ANCA)-associated sm

27 and relapse have not been well described in antineutrophil cytoplasmic antibody (ANCA)-associated sm

28 endency to relapse or remain relapse-free in antineutrophil cytoplasmic antibody (ANCA)-associated va

29 Antineutrophil cytoplasmic antibody (ANCA)-associated va

30 Antineutrophil cytoplasmic antibody (ANCA)-associated va

31 Antineutrophil cytoplasmic antibody (ANCA)-associated va

32 in studies of rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated va

33 acopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated va

34 e first 6 months of therapy of patients with antineutrophil cytoplasmic antibody (ANCA)-associated va

35 in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated va

36 Antineutrophil cytoplasmic antibody (ANCA)-associated va

37 Antineutrophil cytoplasmic antibody (ANCA)-associated va

38 Antineutrophil cytoplasmic antibody (ANCA)-associated va

39 Antineutrophil cytoplasmic antibody (ANCA)-associated va

40 ne of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated va

41 Current remission maintenance therapies for antineutrophil cytoplasmic antibody (ANCA)-associated va

42 g-term prognosis in two autoimmune diseases, antineutrophil cytoplasmic antibody (ANCA)-associated va

43 Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated va

44 llowed remissions in relapsing or refractory antineutrophil cytoplasmic antibody (ANCA)-associated va

45 Antineutrophil cytoplasmic antibody (ANCA)-associated va

46 Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated va

47 RA), systemic lupus erythematosus (SLE), and antineutrophil cytoplasmic antibody (ANCA)-associated va

48 iitis, 16 Churg-Strauss syndrome [CSS]), and antineutrophil cytoplasmic antibody (ANCA)-positive case

49 The triggers that induce antineutrophil cytoplasmic antibody (ANCA)-positive vasc

50 azine, and penicillamine are associated with antineutrophil cytoplasmic antibody (ANCA)-positive vasc

51 Atypical "antineutrophil cytoplasmic antibodies" (ANCA) are presen

52 examines whether exposure of neutrophils to antineutrophil cytoplasmic antibodies (ANCAs) can disrup

53 The development of pathogenic antineutrophil cytoplasmic antibodies (ANCAs) can result

54 the recent advances in understanding of how antineutrophil cytoplasmic antibodies (ANCAs) contribute

55 Antineutrophil cytoplasmic antibodies (ANCAs) have been

56 einase 3 (PR3) is the main target antigen of antineutrophil cytoplasmic antibodies (ANCAs) in PR3-ANC

57 The clinical significance of antineutrophil cytoplasmic antibodies (ANCAs) in the phe

58 PR3 is the prominent target antigen for antineutrophil cytoplasmic antibodies (ANCAs) in Wegener

59 Antineutrophil cytoplasmic antibodies (ANCAs) target pro

60 Testing for atypical antineutrophil cytoplasmic antibodies (ANCAs) was perfor

61 CSS can be accompanied by antineutrophil cytoplasmic antibodies (ANCAs), but most

62 tis where 40% of patients present with serum antineutrophil cytoplasmic antibodies (ANCAs).

63 ti-Saccharomyces cerevisiae, and perinuclear antineutrophil cytoplasmic antibodies and for 3 Crohn's

64 Serological evaluation for antineutrophil cytoplasmic antibodies and human leukocyt

65 id factor, antinuclear antibody, cytoplasmic antineutrophil cytoplasmic antibody, and angiotensin-con

66 Serologic markers such as perinuclear antineutrophil cytoplasmic antibody, anti-Saccharomyces

67 hils that mediates surface expression of the antineutrophil cytoplasmic antibody antigen proteinase 3

68 Antineutrophil cytoplasmic antibodies are a hallmark of

69 Antineutrophil cytoplasmic antibodies are then able to a

70 onset, date of diagnosis, clinical features, antineutrophil cytoplasmic antibody assays, tissue biops

71 nal crisis (SRC), normotensive renal crisis, antineutrophil cytoplasmic antibodies-associated glomeru

72 ed with systemic autoimmune diseases such as antineutrophil cytoplasmic antibodies-associated vasculi

73 is, membranous nephropathy, IgA nephropathy, antineutrophil cytoplasmic antibody-associated glomerulo

74 a on the outcome of renal transplantation in antineutrophil cytoplasmic antibody-associated glomerulo

75 In contrast, antineutrophil cytoplasmic antibody-associated systemic

76 tion and arterial stiffness in patients with antineutrophil cytoplasmic antibody-associated systemic

77 entral nervous system may be involved in the antineutrophil cytoplasmic antibody-associated systemic

78 emission induction regimen for patients with antineutrophil cytoplasmic antibody-associated vasculiti

79 giant cell arteritis, the different forms of antineutrophil cytoplasmic antibody-associated vasculiti

80 (DAH) is a life-threatening manifestation of antineutrophil cytoplasmic antibody-associated vasculiti

81 lasma Exchange and Glucocorticoids in Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculiti

82 segment is affected in C3 glomerulopathy and antineutrophil cytoplasmic antibody-associated vasculiti

83 rythematosus (SLE), rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculiti

84 induction therapy in refractory or relapsing antineutrophil cytoplasmic antibody-associated vasculiti

85 features in renal biopsies of patients with antineutrophil cytoplasmic antibody-associated vasculiti

86 eased incidence of thromboembolic disease in antineutrophil cytoplasmic antibody-associated vasculiti

87 ted at T cells may improve renal outcomes in antineutrophil cytoplasmic antibody-associated vasculiti

88 uss; EGPA), also collectively referred to as antineutrophil cytoplasmic antibody-associated vasculiti

89 r infection in a cohort of 182 patients with antineutrophil cytoplasmic antibody-associated vasculiti

90 d arthritis (RA), Felty's syndrome (FS), and antineutrophil cytoplasmic antibody-associated vasculiti

91 Infection is the leading cause of death in antineutrophil cytoplasmic antibody-associated vasculiti

92 have been implicated in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculiti

93 ractice and improve outcome of patients with antineutrophil cytoplasmic antibody-associated vasculiti

94 f health-related quality of life (HRQOL) for antineutrophil cytoplasmic antibody-associated vasculiti

95 Significant advances in the treatment of antineutrophil cytoplasmic antibody-associated vasculiti

96 ed in four distinct cohorts of patients with antineutrophil cytoplasmic antibody-associated vasculiti

97 LE and 11 patients with active or refractory antineutrophil cytoplasmic antibody-associated vasculiti

98 gests that an infectious agent could trigger antineutrophil cytoplasmic antibody-associated vasculiti

99 nd proteinase 3 is a major target antigen in antineutrophil cytoplasmic antibody-associated vasculiti

100 oid arthritis, systemic lupus erythematosus, antineutrophil cytoplasmic antibody-associated vasculiti

101 Cytoplasmic antineutrophil cytoplasmic antibodies (cANCA) that accom

102 patient with chronic, relapsing cytoplasmic antineutrophil cytoplasmic antibody (cANCA)-associated W

103 omyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies cannot yet replace

104 Many of these illnesses are associated with antineutrophil cytoplasmic antibodies (cytoplasmic, peri

105 Antineutrophil cytoplasmic antibodies directed against a

106 Titers of classic antineutrophil cytoplasmic antibodies fell in associatio

107 The recognition of newer antibodies such as antineutrophil cytoplasmic antibody has given us newer c

108 have provided insight into the occurrence of antineutrophil cytoplasmic antibodies in cocaine-induced

109 ay initiate the activation of neutrophils by antineutrophil cytoplasmic antibodies in patients with W

110 se and pachydermoperiostosis associated with antineutrophil cytoplasmic antibodies is described.

111 A circulating antineutrophil cytoplasmic antibody is found in many pat

112 Perinuclear antineutrophil cytoplasmic antibodies lack sensitivity a

113 opathy, antiglomerular basement membrane and antineutrophil cytoplasmic antibody-mediated crescentic

114 Multisystem large vessel vasculitis (antineutrophil cytoplasmic antibody negative) produced a

115 All were antineutrophil cytoplasmic antibody negative.

116 ASCA, outer-membrane porin C/I2, perinuclear antineutrophil cytoplasmic antibodies, or no/low respons

117 ibodies consisting of high-titre perinuclear antineutrophil cytoplasmic antibodies (p-ANCAs) with spe

118 Two probands were antineutrophil cytoplasmic antibody positive vs. 1 of 27

119 seroreactive to I2, and 23% were perinuclear antineutrophil cytoplasmic antibody positive.

120 py and rituximab in a 13-year-old boy with P-antineutrophil cytoplasmic antibody-positive microscopic

121 hange disease, idiopathic membranous GN, and antineutrophil cytoplasmic antibody-positive pauci-immun

122 es of vasculitis, on the other hand, such as antineutrophil cytoplasmic antibody-positive small vesse

123 ained by differing abilities of proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA)-positive

124 ing of the underlying pathophysiology of the antineutrophil cytoplasmic antibody-related vasculitides

125 Most patients have a circulating antineutrophil cytoplasmic antibody that appears to be t

126 oreactive lymphocyte clones, for example, in antineutrophil cytoplasmic antibodies vasculitis or anti

127 temic lupus erythematosus, cryoglobulinemia, antineutrophil cytoplasmic antibodies+ vasculitis, and d

128 lobulin E against Aspergillus fumigatus, but antineutrophil cytoplasmic antibody was not positive.

129 Perinuclear antineutrophil cytoplasmic antibodies were determined by

130 the treatment of vasculitis associated with antineutrophil cytoplasmic antibodies when standard ther